Recordati Industria Chimica e Farmaceutica stock
REC.MIMILRecordati Industria Chimica e Farmaceutica S.p.A., HealthcareISIN IT0003828271
74Score 74 out of 100, Strong
Price and trend
53 / 100
Price history
−1.8% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.5% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 25).
The price is 2.4% below its 52-week high. Largest decline in 20 years: 47% (October 2007 to October 2008).
Chart figures for advanced users
- SMA 50$58.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$56.22
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)25
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$49.29
- The lowest closing price of the last twelve months.
- Resistance$59.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Recordati Industria Chimica e Farmaceutica S.p.A. belongs to the Medical (Pharmaceuticals) industry (Italy) and, with a market value of $11.92B, is number 5 of 15 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.9B (up 11.8% year on year) and earnings of $491.58M (up 6.5%).
- For fiscal 2026, analysts expect on average revenue of $3.08B (up 6.2%) and adjusted earnings per share of $3.56 (up 13%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 89 of 702 in Healthcare, median 53.
- The P/E is 22 (Medical (Pharmaceuticals) median 35.7, own median of recent years 25.3).
- Our model puts fair value at $75.36, with the price 23% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 13 years.Capital allocation 80
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 92
- Below fair valuePrice 23% below the fair value of $75.36.Valuation 74
Weaknesses
- High debtDebt 1.29 times equity (fiscal 2025), Medical (Pharmaceuticals) median 0.29.Stability 68
Its standout strengths are fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 75 to 74.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- calm price action
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $62.80 and expensive above $94.19 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $56.26 (cash-flow model) and $94.45 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 11.5%. At 12.5% the fair value would be $72.07, at 10.5% it would be $79.59.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (35.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 9.1% on the twelve months before. Revenue has grown solidly since 2006, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 27%, net 17%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 10 Nov 2026EPS reported $0.73 (expected $0.88)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.56+1.2%
- Revenue
- $3.08B−0.4%
- Earnings per share
- $4.12+1.1%
- Revenue
- $3.33B−0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +0.4%2026 full-year targets confirmed: net revenue of EUR 2.73 billion to EUR 2.8 billion.
“We expect net revenue in the range of EUR 2.73 billion to EUR 2.8 billion, driven by high-teen organic growth at constant exchange rates for rare diseases.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Recordati Industria Chimica e Farmaceutica
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Royalty PharmaRPRX $30.71B71
- Swedish Orphan BiovitrumSOBI.ST $16.99B75
- JD Health International6618.HK $16.65B70
- Sino Biopharmaceutical1177.HK $12.58B65
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
ETFs that hold Recordati Industria Chimica e Farmaceutica
Held by 89 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.45% | 0.49% | €26.29M |
| UBS Factor MSCI EMU Low Volatility UCITS ETF EUR disUIMY | 1.32% | 0.25% | €9.28M |
| State Street SPDR S&P Euro Dividend Aristocrats UCITS ETF (Dist)SPYW | 0.73% | 0.30% | €1.88B |
Show 5 more
| iShares EURO STOXX Mid UCITS ETFIQQM | 0.65% | 0.40% | €560.15M |
| State Street SPDR EURO STOXX Low Volatility UCITS ETF (Acc)ZPRL | 0.60% | 0.30% | €29.86M |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETFCEMT | 0.45% | 0.25% | €36.34M |
| iShares FTSE MIB UCITS ETF EUR (Acc)SXRY | 0.39% | 0.33% | €426.85M |
| iShares MSCI EMU Mid Cap UCITS ETF EURIS3H | 0.38% | 0.49% | €570.32M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.